Literature DB >> 17512987

Neuromyelitis optica: changing concepts.

Anu Jacob1, Marcelo Matiello, Dean M Wingerchuk, Claudia F Lucchinetti, Sean J Pittock, Brian G Weinshenker.   

Abstract

Neuromyelitis optica (NMO; Devic's disease) and the NMO spectrum disorders are idiopathic inflammatory demyelinating disorders that affect the central nervous system and have a predilection for optic nerves and spinal cord. The identification of NMO-IgG as a disease-specific marker and aquaporin 4 as the target antigen has renewed interest in NMO. Based on current data, we suspect that autoantibodies arising from peripheral B cells bind to aquaporin 4 expressed on astrocyte foot processes on the abluminal surface of microvessels, activate complement and initiate inflammatory demyelination and necrosis. The development of animal models and further analysis of the association of NMO-IgG with disease severity and treatment response will elucidate the pathobiology of NMO.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512987     DOI: 10.1016/j.jneuroim.2007.04.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  27 in total

Review 1.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

2.  Treatment of neuromyelitis optica: current debate.

Authors:  Tomoko Okamoto; Masafumi Ogawa; Youwei Lin; Miho Murata; Sachiko Miyake; Takashi Yamamura
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

3.  Efficacy of tacrolimus in Sjögren's syndrome-associated CNS disease with aquaporin-4 autoantibodies.

Authors:  Taku Fukuda; Hirokazu Shiraishi; Tatsufumi Nakamura; Keiko Tanaka; Hideki Nakamura; Akira Tsujino; Yoshihiro Nishiura; Toshiro Yoshimura; Masakatsu Motomura; Katsumi Eguchi
Journal:  J Neurol       Date:  2009-05-26       Impact factor: 4.849

4.  Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes.

Authors:  B Carlander; T Vincent; A Le Floch; N Pageot; W Camu; Y Dauvilliers
Journal:  BMJ Case Rep       Date:  2009-02-02

5.  Neuromyelitis optica - an update: 2007-2009.

Authors:  Anu Jacob
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

6.  Late AQP4-IgG seroconversion and shrinking of brainstem MRI lesions in a patient with overlapping CIS/NMOSD.

Authors:  E Giorli; D Franciotta; A Beronio; C Amodeo; S Delucchi; S Boni; C Serrati; A Mannironi; L Benedetti
Journal:  J Neurol       Date:  2016-11-04       Impact factor: 4.849

Review 7.  Neuro-ophthalmic sarcoidosis.

Authors:  Robert P Baughman; Kenneth L Weiss; Karl C Golnik
Journal:  Eye Brain       Date:  2012-03-13

8.  CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics.

Authors:  Ding Chen; Sara J Ireland; Gina Remington; Enrique Alvarez; Michael K Racke; Benjamin Greenberg; Elliot M Frohman; Nancy L Monson
Journal:  J Immunol       Date:  2016-10-26       Impact factor: 5.422

9.  Differential diagnosis of suspected multiple sclerosis: a consensus approach.

Authors:  D H Miller; B G Weinshenker; M Filippi; B L Banwell; J A Cohen; M S Freedman; S L Galetta; M Hutchinson; R T Johnson; L Kappos; J Kira; F D Lublin; H F McFarland; X Montalban; H Panitch; J R Richert; S C Reingold; C H Polman
Journal:  Mult Scler       Date:  2008-09-19       Impact factor: 6.312

10.  Reversible stenosis of large cerebral arteries in a patient with combined Sjögren's syndrome and neuromyelitis optica spectrum disorder.

Authors:  Yuichiro Ii; Akihiro Shindo; Ryogen Sasaki; Yutaka Naito; Keiko Tanaka; Shigeki Kuzuhara
Journal:  Rheumatol Int       Date:  2008-05-21       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.